Proteomic analysis of rat cortical neurons after fluoxetine treatment

Brain Research

Volumn 1135, Issue 1, 2007, Pages 41-51

  Cecconi, Daniela ^a   Mion, Silvia ^b   Astner, Hubert ^a,b   Domenici, Enrico ^b   Righetti, Pier Giorgio ^a   Carboni, Lucia ^b  

^a UNIVERSITY OF VERONA   (Italy)

^b GSK   (Italy)

Author keywords

2D electrophoresis; Antidepressive agent; Fluoxetine; Proteomics; Rat cortical neuron primary culture

Indexed keywords

ANTIDEPRESSANT AGENT; CYCLOPHILIN A; FLUOXETINE; GLUCOSE REGULATED PROTEIN 78; PROTEIN 14 3 3; SEROTONIN;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; CONTROLLED STUDY; DEPRESSION; DRUG MECHANISM; IMAGE ANALYSIS; LONG TERM EXPOSURE; MONOAMINE NERVE CELL; NERVE CELL; NERVE CONDUCTION; NEUROMODULATION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; RAT; SYNAPTIC MEMBRANE;

ANALYSIS OF VARIANCE; ANIMALS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BLOTTING, WESTERN; CELLS, CULTURED; CEREBRAL CORTEX; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; EMBRYO, MAMMALIAN; FLUOXETINE; IMMUNOHISTOCHEMISTRY; NEURONS; PROTEOMICS; RATS; RATS, SPRAGUE-DAWLEY;

RATTUS;

EID: 33846599777     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2006.12.008     Document Type: Article

References (65)

1. Abene M.V., and Hamilton J.D. Resolution of fear of flying with fluoxetine treatment. J. Anxiety Disord. 12 (1998) 599-603
2. Arckens L., Van der Gucht E., Van den Bergh G., Massie A., Leysen I., Vandenbussche E., Eysel U.T., Huybrechts R., and Vandesande F. Differential display implicates cyclophilin A in adult cortical plasticity. Eur. J. Neurosci. 18 (2003) 61-75
3. Aubol B.E., Chakrabarti S., Ngo J., Shaffer J., Nolen B., Fu X.D., Ghosh G., and Adams J.A. Processive phosphorylation of alternative splicing factor/splicing factor 2. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 12601-12606
4. Avramut M., and Achim C.L. Immunophilins in nervous system degeneration and regeneration. Curr. Top. Med. Chem. 3 (2003) 1376-1382
5. Baik S.Y., Jung K.H., Choi M.R., Yang B.H., Kim S.H., Lee J.S., Oh D.Y., Choi I.G., Chung H., and Chai Y.G. Fluoxetine-induced up-regulation of 14-3-3zeta and tryptophan hydroxylase levels in RBL-2H3 cells. Neurosci. Lett. 374 (2005) 53-57
6. Batki S.L., Washburn A.M., Delucchi K., and Jones R.T. A controlled trial of fluoxetine in crack cocaine dependence. Drug Alcohol Depend. 41 (1996) 137-142
7. Beck G., Munno D.W., Levy Z., Dissel H.M., Van-Minnen J., Syed N.I., and Fainzilber M. Neurotrophic activities of trk receptors conserved over 600 million years of evolution. J. Neurobiol. 60 (2004) 12-20
8. Berg D., Holzmann C., and Riess O. 14-3-3 proteins in the nervous system. Nat. Rev., Neurosci. 4 (2003) 752-762
9. Bonenfant D., Coulot M., Towbin H., Schindler P., and van Oostrum J. Characterization of histone H2A and H2B variants and their post-translational modifications by mass spectrometry. Mol. Cell. Proteomics 5 (2006) 541-552
10. Bown C., Wang J.F., MacQueen G., and Young L.T. Increased temporal cortex ER stress proteins in depressed subjects who died by suicide. Neuropsychopharmacology 22 (2000) 327-332
11. Bown C.D., Wang J.F., Chen B., and Young L.T. Regulation of ER stress proteins by valproate: therapeutic implications. Bipolar Disord. 4 (2002) 145-151
12. Caamano C.A., Morano M.I., and Akil H. Corticosteroid receptors: a dynamic interplay between protein folding and homeostatic control. Possible implications in psychiatric disorders. Psychopharmacol. Bull. 35 (2001) 6-23
13. Campostrini N., Areces L.B., Rappsilber J., Pietrogrande M.C., Dondi F., Pastorino F., Ponzoni M., and Righetti P.G. Spot overlapping in two-dimensional maps: a serious problem ignored for much too long. Proteomics 5 (2005) 2385-2395
14. Castren E. Neurotrophins as mediators of drug effects on mood, addiction, and neuroprotection. Mol. Neurobiol. 29 (2004) 289-302
15. Colgan J., Asmal M., Neagu M., Yu B., Schneidkraut J., Lee Y., Sokolskaja E., Andreotti A., and Luban J. Cyclophilin A regulates TCR signal strength in CD4+T cells via a proline-directed conformational switch in Itk. Immunity 21 (2004) 189-201
16. Dam M., Tonin P., De Boni A., Pizzolato G., Casson S., Ermani M., Freo U., Piron L., and Battistin L. Effects of fluoxetine and maprotiline on functional recovery in poststroke hemiplegic patients undergoing rehabilitation therapy. Stroke 27 (1996) 1211-1214
17. DeLong G.R., Teague L.A., and McSwain Kamran M. Effects of fluoxetine treatment in young children with idiopathic autism. Dev. Med. Child Neurol. 40 (1998) 551-562
18. D'Sa C., and Duman R.S. Antidepressants and neuroplasticity. Bipolar Disord. 4 (2002) 183-194
19. Duman R.S., Heninger G.R., and Nestler E.J. A molecular and cellular theory of depression. Arch. Gen. Psychiatry 54 (1997) 597-606
20. Duman R.S., Malberg J., and Thome J. Neural plasticity to stress and antidepressant treatment. Biol. Psychiatry 46 (1999) 1181-1191
21. Egbunike I.G., and Chaffee B.J. Antidepressants in the management of chronic pain syndromes. Pharmacotherapy 10 (1990) 262-270
22. Ellingrod V.L. Pharmacotherapy of primary obsessive-compulsive disorder: review of the literature. Pharmacotherapy 18 (1998) 936-960
23. Favale E., Rubino V., Mainardi P., Lunardi G., and Albano C. Anticonvulsant effect of fluoxetine in humans. Neurology 45 (1995) 1926-1927
24. Frey J., and Darbonne C. Fluoxetine suppresses human cataplexy: a pilot study. Neurology 44 (1994) 707-709
25. Fuller R.W., Wong D.T., and Robertson D.W. Fluoxetine, a selective inhibitor of serotonin uptake. Med. Res. Rev. 11 (1991) 17-34
26. Goldstein D.J., Rampey Jr. A.H., Roback P.J., Wilson M.G., Hamilton S.H., Sayler M.E., and Tollefson G.D. Efficacy and safety of long-term fluoxetine treatment of obesity-maximizing success. Obes. Res. 3 (1995) 481S-490S
27. Heninger G.R., Delgado P.L., and Charney D.S. The revised monoamine theory of depression: a modulatory role for monoamines, based on new findings from monoamine depletion experiments in humans. Pharmacopsychiatry 29 (1996) 2-11
28. Hutchison K.A., Dittmar K.D., Stancato L.F., and Pratt W.B. Ability of various members of the hsp70 family of chaperones to promote assembly of the glucocorticoid receptor into a functional heterocomplex with hsp90. J. Steroid Biochem. Mol. Biol. 58 (1996) 251-258
29. Isobe T., Ichimura T., and Okuyama T. Chemistry and cell biology of neuron- and glia-specific proteins. Arch. Histol. Cytol. 52 (1989) 25-32
30. Ivgy-May N., Tamir H., and Gershon M.D. Synaptic properties of serotonergic growth cones in developing rat brain. J. Neurosci. 14 (1994) 1011-1029
31. Jason L.J., Moore S.C., Lewis J.D., Lindsey G., and Ausio J. Histone ubiquitination: a tagging tail unfolds?. BioEssays 24 (2002) 166-174
32. Kim A.J., Shi Y., Austin R.C., and Werstuck G.H. Valproate protects cells from ER stress-induced lipid accumulation and apoptosis by inhibiting glycogen synthase kinase-3. J. Cell. Sci. 118 (2005) 89-99
33. Kornreich C., Dan B., Verbanck P., Fontaine E., and Pelc I. Divergent responses to fluoxetine from two compulsive, food-related conditions: bulimia nervosa and compulsive water drinking. Biol. Psychiatry 43 (1998) 310-311
34. Lader M. Fluoxetine efficacy vs. comparative drugs: an overview. Br. J. Psychiatry Suppl. 3 (1988) 51-58
35. Lai M., McCormick J.A., Chapman K.E., Kelly P.A., Seckl J.R., and Yau J.L. Differential regulation of corticosteroid receptors by monoamine neurotransmitters and antidepressant drugs in primary hippocampal culture. Neuroscience 118 (2003) 975-984
36. Lejoyeux M. Use of serotonin (5-hydroxytryptamine) reuptake inhibitors in the treatment of alcoholism. Alcohol Alcohol. Suppl. 1 (1996) 69-75
37. Li X., Wang J., and Manley J.L. Loss of splicing factor ASF/SF2 induces G2 cell cycle arrest and apoptosis, but inhibits internucleosomal DNA fragmentation. Genes Dev. 19 (2005) 2705-2714
38. Lin Y.C., Huang Z.H., Jan I.S., Yeh C.C., Wu H.J., Chou Y.C., and Chang Y.C. Development of excitatory synapses in cultured neurons dissociated from the cortices of rat embryos and rat pups at birth. J. Neurosci. Res. 15 (2002) 484-493
39. Maes M., and Meltzer H.Y. The serotonin hypothesis of major depression. In: Bloom F.E., and Kupfer D.J. (Eds). Psychopharmacology. The Fourth Generation of Progress (1995), Raven Press, New York, USA 933-944
40. Matarazzo V., and Ronnett G.V. Temporal and regional differences in the olfactory proteome as a consequence of MeCP2 deficiency. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 7763-7768
41. Muratake T., Hayashi S., Ichimura Y., Morii K., Kuwano R., Ichikawa T., Kumanishi T., Isobe T., Watanabe M., Kondo H., et al. The effect on methamphetamine on the mRNA level for 14.3.3 eta chain in the human cultured cells. Mol. Neurobiol. 11 (1995) 223-230
42. Muscat R., Papp M., and Willner P. Reversal of stress-induced anhedonia by the atypical antidepressants, fluoxetine and maprotiline. Psychopharmacology 109 (1992) 433-438
43. Nahreini P., Hovland A.R., Kumar B., Andreatta C., Edwards-Prasad J., and Prasad K.N. Effects of altered cyclophilin A expression on growth and differentiation of human and mouse neuronal cells. Cell Mol. Neurobiol. 21 (2001) 65-79
44. Nestler E.J., Barrot M., DiLeone R.J., Eisch A.J., Gold S.J., and Monteggia L.M. Neurobiology of depression. Neuron 34 (2002) 13-25
45. Okugawa G., Omori K., Suzukawa J., Fujiseki Y., Kinoshita T., and Inagaki C. Long-term treatment with antidepressants increases glucocorticoid receptor binding and gene expression in cultured rat hippocampal neurones. J. Neuroendocrinol. 11 (1999) 887-895
46. Pariante C.M., Hye A., Williamson R., Makoff A., Lovestone S., and Kerwin R.W. The antidepressant clomipramine regulates cortisol intracellular concentrations and glucocorticoid receptor expression in fibroblasts and rat primary neurones. Neuropsychopharmacology 28 (2003) 1553-1561
47. Pepin M.C., Beaulieu S., and Barden N. Antidepressants regulate glucocorticoid receptor messenger RNA concentrations in primary neuronal cultures. Mol. Brain Res. 6 (1989) 77-83
48. Piubelli C., Cecconi D., Astner H., Caldara F., Tessari M., Carboni L., Hamdan M., Righetti P.G., and Domenici E. Proteomic changes in rat serum, polymorphonuclear and mononuclear leukocytes after chronic nicotine administration. Proteomics 5 (2005) 1382-1394
49. Pratt W.B., Galigniana M.D., Morishima Y., and Murphy P.J. Role of molecular chaperones in steroid receptor action. Essays Biochem. 40 (2004) 41-58
50. Qi W., Liu X., Qiao D., and Martinez J.D. Isoform-specific expression of 14-3-3 proteins in human lung cancer tissues. Int. J. Cancer 113 (2005) 359-363
51. Rao R.V., Peel A., Logvinova A., del Rio G., Hermel E., Yokota T., Goldsmith P.C., Ellerby L.M., Ellerby H.M., and Bredesen D.E. Coupling endoplasmic reticulum stress to the cell death program: role of the ER chaperone GRP78. FEBS Lett. 514 (2002) 122-128
52. Schildkraut J.J. The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am. J. Psychiatry 122 (1965) 509-522
53. Shao L., Sun X., Xu L., Young L.T., and Wang J.F. Mood stabilizing drug lithium increases expression of endoplasmic reticulum stress proteins in primary cultured rat cerebral cortical cells. Life Sci. 78 (2006) 1317-1323
54. Shinozaki A., Arahata K., and Tsukahara T. Changes in pre-mRNA splicing factors during neural differentiation in P19 embryonal carcinoma cells. Int. J. Biochem. Cell Biol. 31 (1999) 1279-1287
55. Steiner M., Korzekwa M., Lamont J., and Wilkins A. Intermittent fluoxetine dosing in the treatment of women with premenstrual dysphoria. Psychopharmacol. Bull. 33 (1997) 771-774
56. Sun L., Bittner M.A., and Holz R.W. Rim, a component of the presynaptic active zone and modulator of exocytosis, binds 14-3-3 through its N terminus. J. Biol. Chem. 278 (2003) 38301-38309
57. Tate C.G., Whiteley E., and Betenbaugh M.J. Molecular chaperones stimulate the functional expression of the cocaine-sensitive serotonin transporter. J. Biol. Chem. 274 (1999) 17551-17558
58. Taurin S., Seyrantepe V., Orlov S.N., Tremblay T.L., Thibault P., Bennett M.R., Hamet P., and Pshezhetsky A.V. Proteome analysis and functional expression identify mortalin as an antiapoptotic gene induced by elevation of [Na+]i/[K+]i ratio in cultured vascular smooth muscle cells. Circ. Res. 91 (2002) 915-922
59. Taylor C., Fricker A.D., Devi L.A., and Gomes I. Mechanisms of action of antidepressants: from neurotransmitter systems to signaling pathways. Cell Signalling 17 (2005) 549-557
60. Tsankova N.M., Berton O., Renthal W., Kumar A., Neve R.L., and Nestler E.J. Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action. Nat. Neurosci. 9 (2006) 519-525
61. Vaidya V.A., and Duman R.S. Depression-Emerging insights from neurobiology. Br. Med. Bull. 57 (2001) 61-79
62. Vaswani M., Linda F.K., and Ramesh S. Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 1 (2003) 154-219
63. Wang J.F., Azzam J.E., and Young L.T. Valproate inhibits oxidative damage to lipid and protein in primary cultured rat cerebrocortical cells. Neuroscience 116 (2003) 485-489
64. Xie C., Markesbery W.R., and Lovell M.A. Survival of hippocampal and cortical neurons in a mixture of MEM+ and B27- supplemented neurobasal medium. Free Radic. Biol. Med. 28 (2000) 665-672
65. Yang J.-W., Juranville J.-F., Höger H., Fountoulakis M., and Lubec G. Molecular diversity of rat brain proteins as revealed by proteomic analysis. Mol. Diversity 9 (2005) 385-396